Posted on

HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure

U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection 

Go to Source

By sf-admin